<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01516983</url>
  </required_header>
  <id_info>
    <org_study_id>BD-IC-IV04</org_study_id>
    <nct_id>NCT01516983</nct_id>
  </id_info>
  <brief_title>Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation</brief_title>
  <official_title>A Single Center, Open Label, Dose-Finding Study to Determine the Safety of Icotinib in Combination With Whole Brain Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Betta Pharmaceuticals Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Betta Pharmaceuticals Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of Icotinib at different
      dose levels in combination with whole brain radiotherapy for NSCLC patients with brain
      metastases and EGFR mutation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The long-term control of brain metastases becomes a clinical challenge. Whole brain
      radiotherapy, the standard treatment for patients with multiple brain metastases, can only
      bring a modest survival improvement around 3-6 months. EGFR-TKIs like icotinib with its
      proven activity in non-small cell lung cancer may provide clinical benefits in such patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>6-12 months</time_frame>
    <description>All cause adverse events (AEs) and serious adverse events (SAEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurological progression-free survival</measure>
    <time_frame>3-6 month</time_frame>
    <description>All cause neurological progress or mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>3-6 months</time_frame>
    <description>All cause progress or mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>6-12 months</time_frame>
    <description>All cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>3-6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measured by FACT-L/LCS 4.0</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive effects</measure>
    <time_frame>3-6 months</time_frame>
    <description>Evaluated according to Mini-Mental Status Examination</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>Icotinib+WBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard whole brain radiotherapy plus icotinib, which is designed to administered at 5 dose according to &quot;3+3&quot; until disease progression or intolerable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>icotinib</intervention_name>
    <description>Level 1: Standard whole brain radiation therapy plus icotinib 125 mg Tid (375 mg per day) from day1 until disease progression or intolerable toxicity.
Level 2: Standard whole brain radiation therapy plus icotinib 250 mg Tid (750 mg per day) from day1 until disease progression or intolerable toxicity.
Level 3: Standard whole brain radiation therapy plus icotinib 375 mg Tid (1125 mg per day) from day1 until disease progression or intolerable toxicity.
Level 4:Standard whole brain radiation therapy plus icotinib 500 mg Tid (1500 mg per day) from day1 until disease progression or intolerable toxicity.</description>
    <arm_group_label>Icotinib+WBRT</arm_group_label>
    <other_name>BPI-2009, Conmana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Whole brain radiotherapy</intervention_name>
    <description>Whole Brain Radiation Therapy (WBRT) for total dose of 37.5Gy in 15 daily fractions beginning after Day 7.</description>
    <arm_group_label>Icotinib+WBRT</arm_group_label>
    <other_name>RT</other_name>
    <other_name>XRT</other_name>
    <other_name>Radiotherapy</other_name>
    <other_name>WBRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytological confirmation of non-small cell lung cancer (NSCLC).

          -  Diagnosis of brain metastases on a Gadolinium-enhanced MRI. More than 3 sites of
             intracranial metastases, or the longest diameter of the intracranial lesion is more
             than 3cm.

          -  Positive EGFR mutation.

        Exclusion Criteria:

          -  Previous usage of EGFR-TKI or antibody to EGFR: gefitinib, erlotinib, herceptin,
             erbitux.

          -  CSF or MRI findings consistent with metastases of spinal cord, meninges or meningeal.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>You Lu</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2012</study_first_submitted>
  <study_first_submitted_qc>January 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2012</study_first_posted>
  <last_update_submitted>February 13, 2014</last_update_submitted>
  <last_update_submitted_qc>February 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>EGFR-TKI</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Icotinib</keyword>
  <keyword>WBRT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

